Second-Line Strategies in the Treatment of Patients With Metastatic Colorectal Cancer
作者： Anthony B. El-Khoueiry , Heinz-Josef Lenz
DOI: 10.1007/978-1-59745-215-1_7
关键词:
摘要: Given the number of active drugs and combinations available, choice second-line therapy in metastatic colorectal cancer can be complicated. It is influenced by many factors, such as nature first-line therapy, potential toxicity one regimen vs another, overall goal treatment for patient. In this chapter, we focus our discussion on therapeutic strategies that used after failure therapy.
springer.com
sci-hub.st 参考文章(31)
R Metzger, C G Leichman, K D Danenberg, P V Danenberg, H J Lenz, K Hayashi, S Groshen, D Salonga, H Cohen, L Laine, P Crookes, H Silberman, J Baranda, B Konda, L Leichman, ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. Journal of Clinical Oncology. ,vol. 16, pp. 309- 316 ,(1998) , 10.1200/JCO.1998.16.1.309
H LENZ, Pharmacogenomics in colorectal cancer Seminars in Oncology. ,vol. 30, pp. 47- 53 ,(2003) , 10.1016/S0093-7754(03)00405-6
Philippe Rougier, Eric Van Cutsem, Emilio Bajetta, Norbert Niederle, Kurt Possinger, Roberto Labianca, Matilde Navarro, Rudolf Morant, Harry Bleiberg, Jacques Wils, Lucile Awad, Patrice Herait, Christian Jacques, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer The Lancet. ,vol. 352, pp. 1407- 1412 ,(1998) , 10.1016/S0140-6736(98)03085-2
A. Grothey, T. Buechele, H. Kroening, K. Ridwelski, P. Reichardt, A. Kretzschmar, M. Clemens, H.J. Schmoll, Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC) European Journal of Cancer. ,vol. 37, ,(2001) , 10.1016/S0959-8049(01)81446-5
S. Alberts, J. Donohue, M. Mahoney, W. Horvath, W. Sternfield, S. Dakhil, R. Levitt, K. Rowland, D. Sargent, R. Goldberg, 259 Patterns of failure after liver resectionin patients receiving FOLFOX4 for metastatic colorectal cancer (MCRC) limited to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study Ejc Supplements. ,vol. 1, ,(2003) , 10.1016/S1359-6349(03)90292-8
Wendy L. Allen, Patrick G. Johnston, Role of Genomic Markers in Colorectal Cancer Treatment Journal of Clinical Oncology. ,vol. 23, pp. 4545- 4552 ,(2005) , 10.1200/JCO.2005.19.752
J Stoehlmacher, D J Park, W Zhang, D Yang, S Groshen, S Zahedy, H-J Lenz, A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer British Journal of Cancer. ,vol. 91, pp. 344- 354 ,(2004) , 10.1038/SJ.BJC.6601975
David Cunningham, Seppo Pyrhönen, Roger D James, Cornelis JA Punt, Tamas F Hickish, Reino Heikkila, Tom B Johannesen, Hans Starkhammar, Clare A Topham, Lucile Awad, Christian Jacques, Patrice Herait, Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer The Lancet. ,vol. 352, pp. 1413- 1418 ,(1998) , 10.1016/S0140-6736(98)02309-5
B. J. Giantonio, P. J. Catalano, N. J. Meropol, P. J. O’Dwyer, E. P. Mitchell, S. R. Alberts, M. A. Schwartz, A. B. Benson, High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 Journal of Clinical Oncology. ,vol. 23, pp. 2- 2 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.2
Robert H. Tukey, Christian P. Strassburg, Peter I. Mackenzie, Pharmacogenomics of Human UDP-Glucuronosyltransferases and Irinotecan Toxicity Molecular Pharmacology. ,vol. 62, pp. 446- 450 ,(2002) , 10.1124/MOL.62.3.446